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How do we maintain the ideals underlying socially funded
and equal health services under demanding conditions of
the twenty-first century? Expenditure on health care
throughout Europe has been rising more rapidly than any
other public service, and pharmaceutical expenditure more
rapidly than other components of healthcare [1]. The
reasons underlying this tendency are well known: demo-
graphic changes, rising patient expectations, stricter clinical
targets, and expensive new technologies [2]. To what extent
is such pressure compatible with the aim of financing a
comprehensive and equitable health service in Europe that
is largely free at the point of delivery? In addition, what can
be done to address these pressures?
A two-day meeting involving 33 leading health care
professionals from nine European Union (EU) countries
was recently convened in Stockholm to address these
issues. A deliberate decision was made not to seek external
funding in order to ensure a free exchange of ideas from
independent academics, regulators, and clinicians. Each
delegate is actively involved either in registration, reim-
bursement, formulary listing, and/ or enhancing the rational
use of drugs in his or her country. The meeting was hosted
by the Karolinska Institute and Stockholm County Council
together with leaders from the ‘Mario Negri’ Institute of
Pharmacological Research in Milan and the universities of
Heidelberg, Liverpool, and Marseilles.
The meeting identified that optimizing the use of new
expensive technologies represented the major challenge
faced by health care services throughout Europe, especially
with pharmaceutical companies seeking to overcome lost
revenues from patent expiry estimated at over $100 bn
USD per year over the next 4 years [3]. Whereas increasing
the proportion of health care expenditure allocated to drugs
is not intrinsically regrettable, ongoing pressure reinforces
the need to ensure optimum stewardship of national
pharmaceutical expenditure. This was encapsulated in the
agreed vision which was “to ensure robust systems are in
place in Europe to enhance the rational use of drugs,
including new, expensive drugs, to improve health.” The
delegates believed these objectives could be achieved by
collaborating and developing pan-European strategies to
shared problems and pressures that can be adapted locally.
Guidelines and incentives are seen as beneficial to en-
hance rational use in line with an approach that has became
known as the “five E’s,” namely: Evaluation, Economics,
Enforcement, Education, and Engineering. Rational use of
new, expensive drugs would also be enhanced through
obtaining greater transparency in the information provided
by pharmaceutical companies to regulators and national
reimbursement agencies [4, 5]. Ensuring a basic infrastruc-
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in Stockholm – at Conference Hall Piperska Muren – a meeting centre
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ture is in place for early and ongoing assessment of the value
of new drugs was also seen as a key step for the future.
Developing common databases and registries among Euro-
pean countries to capture utilization, safety, and outcome
data of new drugs and using such databases to assess their
clinical effectiveness and cost-effectiveness in real-world
practice would also be very beneficial to refine future
guidance. Last, it was believed that independent pan-
European studies are essential to generate robust and
reliable evidence to enhance the future rational use of new,
expensive drugs, building on, for instance, the experience in
Italy [6].
The Piperska group is developing a range of pan-
European collaborative work programs to pursue these
objectives, which it aims to have funded and operational by
2010. Representatives from a “new” European country,
Poland, emphasized the potential value of collaboration with
“old” European countries to identify strategies and policies
to better manage the development of their health care
systems. Such collaboration between new and old Europe
is at the heart of the work programs being developed.
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